Nobody can say yet which pill is better for weight loss, because no head-to-head trial compares Foundayo (orforglipron) with the Wegovy pill (semaglutide tablets) in people with obesity. Each maker has published an indirect comparison that favors its own drug: Novo Nordisk's, in adults without diabetes, favors the Wegovy pill, and Lilly's, released September 29, 2026 in adults with type 2 diabetes, favors Foundayo. What you can compare today is how you take each pill, how the side effects looked in trials, and who should avoid them.
| Head-to-head trial in obesity | None |
| Novo Nordisk's indirect comparison (Apr 2, 2026) | Wegovy pill 25 mg about 3 percentage points more weight loss than orforglipron 36 mg (the dose Novo says equals the 17.2 mg tablet), in adults without diabetes |
| Lilly's indirect comparison (Sep 29, 2026) | Foundayo 17.2 mg 1.5% more weight loss than oral semaglutide 25 mg at 52 weeks, in adults with type 2 diabetes |
| Foundayo label result | 17.2 mg: average weight change of -11.1% at 72 weeks versus -2.1% on placebo (adults without diabetes) |
| How you take it | Foundayo: once daily, any time, with or without food. Wegovy pill: once daily on an empty stomach with up to 4 ounces of water, then wait 30 minutes |
| Top dose | Foundayo 17.2 mg; Wegovy pill 25 mg |
| Heart indication | Wegovy tablets are labeled to reduce major cardiovascular events in adults with established heart disease and obesity or overweight. Foundayo's FDA-approved use is weight management only |
| Shared warning | Both carry a boxed warning for thyroid C-cell tumors |
Is Foundayo better than the Wegovy pill for weight loss?
The honest answer is that it is not known. The Foundayo prescribing information reports two placebo-controlled trials. In Trial 1 (3,127 adults with obesity or overweight, no diabetes), average weight change at 72 weeks was -7.4% on 5.5 mg, -8.3% on 9 mg and -11.1% on 17.2 mg, against -2.1% on placebo. At 17.2 mg, 71.5% lost at least 5% of body weight and 54.5% lost at least 10%, versus 26.8% and 13% on placebo. In Trial 2 (1,613 adults with type 2 diabetes), 17.2 mg produced -9.6% versus -2.5% on placebo.
Two cautions apply when you read those numbers. First, the trials used an investigational formulation at doses the label treats as equivalent to the tablets you would be prescribed. Second, more people in the placebo group stopped the study drug in Trial 1 (30%) than in the Foundayo groups (22% to 24%), which is the kind of imbalance explained in this guide to differential dropout in trials. The label handles missing data with statistical imputation.
The Wegovy prescribing information describes the tablet's safety data from a 64-week trial of 204 adults with obesity or overweight and no diabetes. Weight results from that trial are what Novo's comparison below relies on. Because the two drugs were tested in different trials with different people, lengths and sizes, you should not subtract one result from the other.
What did Novo Nordisk's comparison find?
Novo Nordisk's April 2 release describes ORION, an indirect comparison of Wegovy tablets 25 mg (OASIS 4 trial data) with orforglipron 36 mg (ATTAIN-1 trial data) in adults without diabetes. Novo says the approved 17.2 mg Foundayo tablet is equivalent to the 36 mg capsules used in phase 3 trials.
- Weight loss: Novo reports oral semaglutide produced 3.2 percentage points more weight loss (95% CI -5.9 to -0.4) regardless of whether people stayed on treatment, and 3.0 points more (-5.8 to -0.3) if everyone stayed on treatment. Both intervals end close to zero.
- Stopping treatment: Novo reports about 4 times higher odds of stopping because of any side effect with orforglipron (odds ratio 4.1, CI 1.3 to 13.0) and about 14 times higher odds of stopping because of stomach and bowel side effects (13.9, CI 2.0 to 96.0).
- Novo's own limits: other unaccounted differences may remain, protocols differed between trials, and the tolerability gap should be read with caution because few people stopped. The very wide intervals reflect that.
Novo also reports a survey of 800 US adults in which 84% favored a profile resembling oral semaglutide over one resembling orforglipron. Novo lists selection bias and hypothetical profiles among its limits, and the survey ran before Foundayo's approval. It tells you what people said they preferred, not how either drug performed.
What did Lilly's September 29 comparison find?
Lilly's release reports an indirect comparison in adults with type 2 diabetes, using ACHIEVE-3 and PIONEER PLUS data, presented at a European diabetes meeting. At 52 weeks, Lilly says Foundayo 17.2 mg was associated with 1.5% more weight loss (95% CI -2.7% to -0.2%) and 0.3% more A1C reduction (CI -0.6% to -0.1%) than oral semaglutide 25 mg. Other statistical methods gave 1.5% to 2.4% more weight loss.
Lilly's own executive is quoted saying the results suggest Foundayo “may deliver A1C and weight lowering that is similar to the 25 mg dose of oral semaglutide.” That is a softer statement than the headline. Lilly's footnote also says the 25 mg dose is not approved in the US for type 2 diabetes, and that Novo Nordisk has applied for it. Foundayo is approved only for weight management, and the Wegovy label says its tablets have not been studied for weight reduction in adults with type 2 diabetes. This comparison therefore cannot tell you which pill is better for weight loss if you have diabetes.
The same release describes ACHIEVE-3, a randomized, open-label, 52-week trial of 1,698 adults with type 2 diabetes. It compared Foundayo 9 mg and 17.2 mg with oral semaglutide 7 mg and 14 mg. Lilly reports weight loss of 6.7% and 9.2% on Foundayo versus 3.7% and 5.3% on oral semaglutide, and A1C reductions of 1.9% and 2.2% versus 1.1% and 1.4%. Those semaglutide doses are lower than the 25 mg weight-loss dose, so this is not a test of the Wegovy pill.
Which pill has the milder side effects?
Both labels warn that rates from one trial cannot be directly compared with rates from another. With that in mind, here is what each label reports. Foundayo figures are 17.2 mg versus placebo from the pooled trials (3,155 treated adults, about a third with type 2 diabetes). The Wegovy tablet figures come from the single 204-person trial, which excluded type 2 diabetes.
| Measure | Foundayo 17.2 mg (placebo) | Wegovy tablet 25 mg (placebo) |
|---|---|---|
| Stopped because of any side effect | 10% (3%) | 6.9% (5.9%) |
| Stopped because of stomach and bowel side effects | 6% (0.7%) | 3.4% (2%) |
| Severe stomach and bowel reactions | About 3% across Foundayo-treated patients (1%) | 2% (0%) |
| Gallstones | 1% pooled across doses (0.7%) | 2.5% (1%) |
| Altered skin sensation (dysesthesia) | 1% (0.1%) | 5% (0%) |
| Heart rate increase | 4 to 5 beats per minute (0.5 on placebo) | Label reports similar findings to the injection, which raised rates by 1 to 4 beats per minute |
For Foundayo, the label lists these common effects at 17.2 mg versus placebo: nausea 35% (10%), diarrhea 25% (11%), constipation 24% (9%), vomiting 24% (4%), dyspepsia 13% (4%), abdominal pain 14% (7%), headache 9% (7%), fatigue 9% (4%), belching 8% (1%), and hair loss 5% (2%). Any stomach or bowel reaction occurred in 69% versus 37%. Nausea, vomiting and diarrhea were highest while the dose was rising and eased over time. Hair loss was linked to weight reduction and was reported more in women (7%) than men (0.9%).
For Wegovy, the label says the tablet's common reactions were similar in type and frequency to the injection's. For the injection, 73% had a stomach or bowel reaction versus 47% on placebo, including nausea (44% vs 16%), vomiting (25% vs 6%) and diarrhea (30% vs 16%), mostly during dose escalation.
Both labels carry warnings for pancreatitis, kidney injury from dehydration, gallbladder disease, low blood sugar with insulin or sulfonylureas, allergic reactions, diabetic retinopathy, and aspiration during anesthesia. Tell anyone planning a procedure with sedation that you take either pill. You can report side effects to the FDA at 1-800-FDA-1088 or fda.gov (MedWatch).
How do you take each pill?
| Foundayo | Wegovy tablet | |
|---|---|---|
| Timing | Once daily, any time, with or without food | Once daily in the morning on an empty stomach, with up to 4 ounces of plain water |
| After the dose | No wait | Wait at least 30 minutes before food, drinks or other oral medicines |
| Starting steps | 0.8 mg, then 2.5 mg, then 5.5 mg, at least 30 days each; then 9, 14.5 or 17.2 mg as tolerated, at least 30 days per step | 1.5 mg for 30 days, then 4 mg, then 9 mg, then 25 mg from day 91 |
| Missed dose | Take as soon as possible; no doubling. If 7 or more in a row are missed, restart at a lower dose | Skip it and take the next dose the following day |
| Tablets | Swallow whole, one per day | Swallow whole, one per day |
Foundayo is a small-molecule (non-peptide) drug, according to Lilly. The FDA's approval release highlights that it is a pill “which does not need to be taken on an empty stomach.” Semaglutide is a peptide, which is why the Wegovy tablet contains an absorption enhancer (SNAC) and needs the empty-stomach routine.
Interactions differ. Foundayo's label says to avoid strong CYP3A4 inducers, cap the Foundayo dose at 9 mg with strong CYP3A4 inhibitors, and not exceed simvastatin 20 mg daily. For oral birth control pills, it advises a non-oral method or a barrier method for 30 days after starting and after each dose increase. The Wegovy label reports levothyroxine exposure rose 33% with the tablet and advises closer monitoring of oral medicines with a narrow safety margin. Both drugs delay stomach emptying, which can change how other oral medicines are absorbed. Your pharmacist or prescriber should review your full medicine list.
Is the Wegovy pill as effective as the Wegovy injection?
The Wegovy label does not give a head-to-head weight-loss comparison of the two forms. It does say that in people without type 2 diabetes, average semaglutide blood levels were similar with the 25 mg tablet daily and the 2.4 mg injection weekly. In people with type 2 diabetes, levels were lower with the tablet, and tablet blood levels varied more from person to person in every group. The label says some people with type 2 diabetes on the tablet may have levels too low to work, and suggests considering the injection if the response is inadequate. It also says to consider the 1.7 mg injection if the 25 mg tablet is not tolerated. Any switch is a decision for you and your prescriber.
Why do people stop Wegovy?
The label shows the trial reasons. In the tablet trial, 6.9% stopped because of side effects (5.9% on placebo), mainly stomach and bowel reactions. In the injection trials, 6.8% stopped (3.2% on placebo), most often for nausea, vomiting and diarrhea. If side effects are your concern, ask your prescriber about slowing dose increases; the Wegovy label itself says to consider delaying escalation if a dose is not tolerated. Reasons such as cost or access depend on your coverage, so ask your pharmacy and insurer.
Does either pill help the heart?
The Wegovy label lists a cardiovascular indication for the tablets: reducing the risk of heart attack, stroke or cardiovascular death in adults with established cardiovascular disease and obesity or overweight. Foundayo is approved for weight management only.
Lilly's September 30 release reports ACHIEVE-4, an open-label trial of 2,749 adults with type 2 diabetes comparing Foundayo with insulin glargine, not with semaglutide. Lilly reports a 16% lower risk of major cardiovascular events (hazard ratio 0.84, CI 0.59 to 1.20), which met the trial's non-inferiority goal. Lilly also reports lower cardiovascular death and all-cause death, but its footnotes say those analyses were not controlled for multiple testing. Treat them as signals, not proof. The FDA approval letter required Lilly to complete this trial and submit adjudicated heart-event and liver-injury data as a postmarketing requirement.
Who should not take either pill?
- Thyroid cancer history: both labels contraindicate use with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Foundayo's label notes orforglipron did not cause tumors in rodents because it is not active in rats or mice, and that the human relevance of this class effect has not been determined.
- Serious allergy: anyone with a prior serious reaction to the drug or its ingredients.
- Pregnancy and breastfeeding: both labels say to stop when pregnancy is recognized. The Wegovy label says to stop at least 2 months before a planned pregnancy. Neither label recommends breastfeeding while on the tablets.
- Other GLP-1 drugs: neither should be combined with another GLP-1 receptor agonist.
- Severe stomach emptying problems (gastroparesis): both labels do not recommend use.
- Severe liver impairment: Foundayo's label does not recommend use.
- Children: safety and effectiveness of both tablets have not been established in children.
If you take insulin or a sulfonylurea, the labels say low blood sugar risk rises and your clinician may need to adjust those doses. Do not change any medicine without your clinician.
How do they compare with Zepbound and semaglutide injections?
Zepbound is Lilly's weekly injection containing tirzepatide. Wegovy injection is weekly semaglutide, starting at 0.25 mg and usually reaching 2.4 mg. No trial in the evidence compares Foundayo directly with Zepbound or with semaglutide injections, so any ranking you see online is a cross-trial guess. For how the injectables stack up, see our tirzepatide vs semaglutide comparison. For Foundayo's background and mechanism, see our orforglipron research review.
The practical difference is the delivery: a daily pill with no food rules (Foundayo), a daily pill with strict morning rules (Wegovy tablet), or a weekly injection. Wegovy injection also has indications the pills do not, such as adolescent obesity from age 12 and a liver-disease indication.
What does it cost, and does Medicare help?
Cash prices change often and depend on dose and pharmacy, so confirm with your pharmacy, your insurer and each maker's patient program. On coverage, CMS says its Medicare GLP-1 Bridge runs from July 1, 2026 to December 31, 2027 and gives eligible Part D members access to certain GLP-1 drugs with a $50 copay. The Part D deductible does not apply. The CMS page does not list which drugs are included, so check Medicare.gov/glp1bridge or call 1-800-MEDICARE (1-800-633-4227) before assuming either pill qualifies.
What are the reviews and Reddit threads like?
Online reviews and forum posts are self-selected, mix doses and starting weights, and cannot show which drug works better. The trial tables above are more reliable for comparing side effects. Your prescriber or pharmacist can tell you what they see in practice with each pill.
What is the most successful weight-loss pill, and what about over-the-counter or rapid options?
The two FDA-approved GLP-1 weight-loss pills covered here are prescription medicines, and Foundayo was approved April 1, 2026 in a fast-tracked FDA review. Both are labeled for use with a reduced-calorie diet and more physical activity. For claims about celebrity pills, over-the-counter products or rapid weight loss, ask a clinician what is safe and supported for your health history rather than relying on social media.
Before you order
- Ask your prescriber whether you have any thyroid cancer history, gastroparesis, liver problems, diabetes treatment or planned surgery that rules out either pill.
- Ask whether you can follow the Wegovy pill's empty-stomach, 30-minute routine every morning.
- Have your pharmacist check your other medicines, including simvastatin, levothyroxine and birth control pills.
- If you have type 2 diabetes, ask which option fits, since neither comparison above answers the weight-loss question for you.
- Confirm cash price or insurance coverage for the exact dose before you start.
By MeridianMedicalCentre.com Health Research Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.